Case studies have steered an elevated danger of gynecomastia with HMG‐CoA reductase inhibitors (i.e. statins). A current meta‐evaluation additionally discovered that statins lower circulating testosterone ranges in males. We investigated whether or not statin use was related to an elevated danger of gynecomastia.
Case management examine.
A cohort of sufferers from a random pattern of 9,053,240 US topics from the PharMetrics Plus™ well being claims database from 2006 to 2016 was created.
New instances of gynecomastia requiring not less than two ICD‐9 codes have been recognized from the cohort and matched to 10 controls by comply with‐up time and age utilizing density‐primarily based sampling. Charge ratios (RRs) for previous customers of statins have been computed utilizing conditional logistic regression adjusting for alcoholic cirrhosis, hyperthyroidism, testicular most cancers, Klinefelter syndrome, weight problems, hypogonadism, hyperprolactinemia and use of spironolactone, ketoconazole, H2 receptor antagonists (H2 blockers), risperidone, testosterone and androgen deprivation remedy.
Our cohort included 6,147 instances of gynecomastia and 61,470 corresponding matched controls. The adjusted RR for present, current and previous statin use with respect to gynecomastia was 1.19 (1.04‐1.36), 1.38 (1.15‐1.65) and 1.20 (1.03‐1.40) respectively.
Statin use is related to an elevated danger of creating gynecomastia. Clinicians ought to be cognizant of this impact and educate sufferers accordingly.